Heska Corp (NASDAQ:HSKA) – Research analysts at B. Riley lowered their Q4 2018 earnings per share estimates for Heska in a note issued to investors on Wednesday, November 7th. B. Riley analyst K. Anderson now forecasts that the medical research company will post earnings per share of $0.71 for the quarter, down from their prior estimate of $0.77. B. Riley also issued estimates for Heska’s Q2 2019 earnings at $0.36 EPS, Q3 2019 earnings at $0.42 EPS, Q4 2019 earnings at $0.68 EPS and FY2019 earnings at $1.96 EPS.
Heska (NASDAQ:HSKA) last issued its earnings results on Tuesday, November 6th. The medical research company reported $0.46 EPS for the quarter, topping the Zacks’ consensus estimate of $0.35 by $0.11. Heska had a net margin of 1.01% and a return on equity of 11.48%. The business had revenue of $30.96 million for the quarter, compared to the consensus estimate of $31.14 million.
Shares of HSKA opened at $102.32 on Thursday. The company has a market capitalization of $756.30 million, a price-to-earnings ratio of 49.43 and a beta of 0.73. Heska has a twelve month low of $56.59 and a twelve month high of $114.50.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Alps Advisors Inc. purchased a new position in shares of Heska in the second quarter worth $388,000. Russell Investments Group Ltd. raised its holdings in shares of Heska by 16.0% in the second quarter. Russell Investments Group Ltd. now owns 39,885 shares of the medical research company’s stock worth $4,140,000 after buying an additional 5,490 shares during the last quarter. Macquarie Group Ltd. purchased a new position in shares of Heska in the second quarter worth $234,000. American Century Companies Inc. raised its holdings in shares of Heska by 10.0% in the second quarter. American Century Companies Inc. now owns 48,577 shares of the medical research company’s stock worth $5,042,000 after buying an additional 4,401 shares during the last quarter. Finally, Piedmont Investment Advisors LLC purchased a new position in shares of Heska in the second quarter worth $162,000. 88.63% of the stock is owned by institutional investors and hedge funds.
In other Heska news, EVP Steven M. Eyl sold 33,351 shares of the firm’s stock in a transaction on Monday, August 13th. The shares were sold at an average price of $98.49, for a total value of $3,284,739.99. Following the completion of the transaction, the executive vice president now owns 15,401 shares of the company’s stock, valued at $1,516,844.49. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Jason A. Napolitano sold 2,500 shares of the firm’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $113.50, for a total transaction of $283,750.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 56,777 shares of company stock valued at $5,751,062. Corporate insiders own 14.70% of the company’s stock.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Further Reading: How is an ETF different from a mutual fund?
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.